Skip to main content
SpringerLink
Log in

SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

A Correction to this article was published on 16 February 2022

This article has been updated

Abstract

Heart failure is an important medical condition that is prevalent in older adults. Multiple therapies have been identified that improve clinical outcome in heart failure with a reduced ejection fraction. Conversely, this has not been the case in heart failure with preserved ejection fraction (HFpEF). Until now, empagliflozin is the first therapy that has convincingly been shown to improve clinical outcome in HFpEF. Importantly, some key points should be considered to better understand the impact of empagliflozin on the patient trajectory, particularly in older adults with HFpEF. In this current opinion article, we have therefore provided more information on how to translate the findings of the EMPEROR-Preserved trial to the setting of older adults, with a focus on the impact of empagliflozin on hospitalizations, both heart failure-related and all-cause. To better understand the importance of EMPEROR-Preserved findings, we compared these findings with previous relevant HFpEF and heart failure with reduced ejection fraction (HFrEF) trials and provided information on ongoing trials in the HFpEF setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

    Article  CAS  Google Scholar 

  2. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743.

    Article  Google Scholar 

  3. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–56.

    Article  Google Scholar 

  4. Lam CSP, Solomon SD. Classification of heart failure according to ejection fraction: JACC review topic of the week. J Am Coll Cardiol. 2021;77(25):3217–25.

    Article  Google Scholar 

  5. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

    Article  CAS  Google Scholar 

  6. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    Article  CAS  Google Scholar 

  7. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

    Article  CAS  Google Scholar 

  8. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.

    Article  CAS  Google Scholar 

  9. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.

    Article  CAS  Google Scholar 

  10. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.

    Article  CAS  Google Scholar 

  11. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100–16.

    Article  Google Scholar 

  12. Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019;40(26):2155–63.

    Article  Google Scholar 

  13. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–92.

    Article  CAS  Google Scholar 

  14. Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res. 2021. https://doi.org/10.1093/cvr/cvab271 (Epub 13 Aug 2021).

    Article  PubMed  Google Scholar 

  15. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. Eur Heart J. 2021;42(48):4887–90.

    Article  Google Scholar 

  16. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  Google Scholar 

  17. Aguilar-Gallardo JS, Correa A, Contreras JP. Cardio-renal benefits of SGLT2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2021. https://doi.org/10.1093/ehjcvp/pvab056 (Epub 15 Jul 2021).

    Article  PubMed  Google Scholar 

  18. Anker SD, Khan MS, Shahid I, Filippatos G, Coats AJS, Butler J. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. Eur J Heart Fail. 2021;23(8):1250–5.

    Article  CAS  Google Scholar 

  19. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.

    Article  CAS  Google Scholar 

  20. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144(16):1284–94.

    Article  Google Scholar 

  21. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab798 (Epub 8 Dec 2021).

    Article  PubMed  PubMed Central  Google Scholar 

  22. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

    Article  CAS  Google Scholar 

  23. Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation. 2021;144(15):1193–5.

    Article  Google Scholar 

  24. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598–617.

    Article  CAS  Google Scholar 

  25. Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, et al. Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: a randomized clinical trial. JAMA Intern Med. 2018;178(3):375–82.

    Article  Google Scholar 

  26. Ceschi A, Noseda R, Pironi M, Lazzeri N, Eberhardt-Gianella O, Imelli S, et al. Effect of Medication Reconciliation at Hospital Admission on 30-Day Returns to Hospital: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(9):e2124672.

    Article  Google Scholar 

  27. Van Der Linden L, Hias J, Walgraeve K, Loyens S, Flamaing J, Spriet I, et al. Factors associated with the number of clinical pharmacy recommendations: findings from an observational study in geriatric inpatients. Acta Clin Belg. 2021;76(2):119–26.

    Article  Google Scholar 

  28. Tisminetzky M, Gurwitz JH, Fan D, Reynolds K, Smith DH, Magid DJ, et al. Multimorbidity burden and adverse outcomes in a community-based cohort of adults with heart failure. J Am Geriatr Soc. 2018;66(12):2305–13.

    Article  Google Scholar 

  29. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42(6):681–3.

    Article  Google Scholar 

  30. Mordi IR, Ouwerkerk W, Anker SD, Cleland JG, Dickstein K, Metra M, et al. Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. Eur J Heart Fail. 2021;23(3):436–44.

    Article  CAS  Google Scholar 

  31. Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, et al. Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations? JACC Heart Fail. 2020;8(9):725–38.

    Article  Google Scholar 

  32. Ouwerkerk W, Teng TK, Tromp J, Tay WT, Cleland JG, van Veldhuisen DJ, et al. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. Eur J Heart Fail. 2020;22(8):1472–82.

    Article  CAS  Google Scholar 

  33. Van der Linden L, Hias J, Walgraeve K, Flamaing J, Tournoy J, Spriet I. Clinical pharmacy services in older inpatients: an evidence-based review. Drugs Aging. 2020;37(3):161–74.

    Article  Google Scholar 

  34. Walgraeve K, Van der Linden L, Flamaing J, Fagard K, Spriet I, Tournoy J. Feasibility of optimizing pharmacotherapy in heart failure patients admitted to an acute geriatric ward: role of the clinical pharmacist. Eur Geriatr Med. 2018;9(1):103–11.

    Article  Google Scholar 

  35. Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217–25.

    Article  CAS  Google Scholar 

  36. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.

    Article  CAS  Google Scholar 

  37. Tromp J, Ponikowski P, Salsali A, Angermann CE, Biegus J, Blatchford J, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826–34.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, University Hospitals Leuven, Leuven, Belgium

    Julie Hias, Laura Hellemans, Karolien Walgraeve & Lorenz Van der Linden

  2. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

    Julie Hias, Laura Hellemans & Lorenz Van der Linden

  3. Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium

    Jos Tournoy

  4. Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

    Jos Tournoy

Authors
  1. Julie Hias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Hellemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karolien Walgraeve
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jos Tournoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lorenz Van der Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenz Van der Linden.

Ethics declarations

Funding

No funding was received to assist in the preparation of this manuscript.

Conflict of interest

Julie Hias, Laura Hellemans, Karolien Walgraeve, Jos Tournoy, and Lorenz Van der Linden declare that there are no conflicts of interest.

Ethics approval

Not Applicable.

Consent to participate

Not Applicable.

Consent for publication

Not Applicable.

Availability of data and material

Not Applicable.

Code availability

Not Applicable.

Author contributions

The first draft was written by Lorenz Van der Linden. All authors commented on previous versions of the manuscript and read and approved the final manuscript.

Additional information

The original Online version of this article was revised: The third sentence of the first paragraph in section 3.3 has been incorrectly Published.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hias, J., Hellemans, L., Walgraeve, K. et al. SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Drugs Aging 39, 185–190 (2022). https://doi.org/10.1007/s40266-022-00920-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-022-00920-7

Search

Navigation